nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.36485/1561-6274-2022-26-2-25-33nefr-2112Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESРАЦИОНАЛЬНАЯ ПОДДЕРЖИВАЮЩАЯ ИММУНОСУПРЕССИВНАЯ ТЕРАПИЯ ДЛЯ РЕЦИПИЕНТОВ ПОЧЕЧНОГО ТРАНСПЛАНТАТА ПОЖИЛОГО ВОЗРАСТА. ОБЗОР ЛИТЕРАТУРЫRATIONAL MAINTENANCE IMMUNOSUPPRESSION FOR ELDERLY RENAL TRANSPLANT RECIPIENTS. THE LITERATURE REVIEWhttps://orcid.org/0000-0003-1773-9971ФедулкинаВ. А.FedulkinaV. A.

Вероника Андреевна Федулкина

129110, Москва, ул. Щепкина, д. 61/2Тел.: +7 926 398-6703

Veronika A. Fedulkina, MD

129110, Moscow, Schepkina str., 61/2Tel.: +7 926 398-6703

v.fedulkina@mail.ruhttps://orcid.org/0000-0001-8497-0693ВатазинА. В.VatazinA. V.

Андрей Владимирович Ватазин, проф., д-р мед. наук

129110, Москва, ул. Щепкина, д. 61/2Тел.: +7 916 148-2790

Andrey V. Vatazin, Prof., MD, PhD, DMedSci

129110, Moscow, Schepkina str., 61/2Tel.: +7 916 148-2790

vatazin@yandex.ruhttps://orcid.org/0000-0002-7079-8383КильдюшевскийА. В.KildyushevskiyA. V.

Александр Вадимович Кильдюшевский, проф., д-р мед. наук

129110, Москва, ул. Щепкина, д. 61/2Тел.: +7 903 614-8665

Alexandr V. Kildyushevskiy, Prof., MD, PhD, DMedSci

129110, Moscow, Schepkina str., 61/2Tel.: +7 903 614-8665

kildushev@yandex.ruhttps://orcid.org/0000-0001-5405-7887ЗулькарнаевА. Б.ZulkarnayevA. B.

Алексей Батыргараевич Зулькарнаев, проф., д-р мед. наук

129110, Москва, ул. Щепкина, д. 61/2Тел.: +7 916 705-9899

Alexey B. Zulkarnayev, Prof., MD, PhD, DMedSci

129110, Moscow, Schepkina str., 61/2Tel.: +7 916 705-9899

7059899@gmail.comhttps://orcid.org/0000-0002-3015-1382ГубинаД. В.GubinaD. V.

Дарья Владимировна Губина

129110, Москва, ул. Щепкина, д. 61/2Тел.: +7 926 326-6646

Darya V. Gubina

129110, Moscow, Schepkina str., 61/2Tel.: +7 926 326-6646

penzevadv@yandex.ruХирургическое отделение трансплантации почки, Московский областной научно-исследовательский клинический институт им. М.Ф. ВладимирскогоРоссияSurgical Division of kidney transplantation in Moscow Regional Research and Clinical InstituteRussian Federation2022200620222622533Copyright © Федулкина В.А., Ватазин А.В., Кильдюшевский А.В., Зулькарнаев А.Б., Губина Д.В., 20222022Федулкина В.А., Ватазин А.В., Кильдюшевский А.В., Зулькарнаев А.Б., Губина Д.В.Fedulkina V.A., Vatazin A.V., Kildyushevskiy A.V., Zulkarnayev A.B., Gubina D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/2112

Основным принципом иммуносупрессивной терапии на взгляд многих авторов постепенно становится необходимость учитывать все преимущества и недостатки назначаемых препаратов у каждого конкретного пациента. Индивидуализация пожизненной иммуносупрессии выступает в качестве основного фактора выживаемости трансплантата в отдаленном периоде и, соответственно, жизни реципиента. В данном обзоре проанализирована литература, посвященная изменению фармакокинетики и фармакодинамики иммуносупрессивных препаратов у пожилых пациентов и оценены перспективы для коррекции иммуносупрессивной терапии при трансплантации почки пожилым пациентам.

The main principle of immunosuppressive therapy, in the opinion of many authors, is gradually becoming the need to take into account all the advantages and disadvantages of the prescribed drugs in each particular patient. Individualization of lifelong immunosuppression acts as the main factor in long-term graft survival and, accordingly, in the life of the recipient. This review analyzes the literature on changes in the pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly patients, and assesses the prospects for the correction of immunosuppressive therapy in kidney transplantation in elderly patients.

трансплантация почкистарениеиммуносенесценцияиммуносупрессивная терапияkidney transplantationagingimmunosenescenceimmunosuppressive therapyРабота выполнена при поддержке гранта Президента Российской Федерации для государственной поддержки молодых российских ученых № МК-63.2020.7The work was carried out according to the grant of the President of the Russian Federation for state support of young Russian scientists No. MK-63.2020.7ReferencesBauer AC, Franco RF, Manfro RC. Immunosuppression in Kidney Transplantation: State of the Art and Current Protocols. Curr Pharm Des 2020; 26(28):3440–3450. doi:10.2174/1381612826666200521142448Bauer AC, Franco RF, Manfro RC. Immunosuppression in Kidney Transplantation: State of the Art and Current Protocols. Curr Pharm Des 2020; 26(28):3440–3450. doi:10.2174/1381612826666200521142448Nian Y, Minami K, Maenesono R, Iske J, Yang J, Azuma H et al. Changes of T-cell Immunity Over a Lifetime. Transplantation 2019; 103(11): 2227–2233. doi:10.1097/TP.0000000000002786Nian Y, Minami K, Maenesono R, Iske J, Yang J, Azuma H et al. Changes of T-cell Immunity Over a Lifetime. Transplantation 2019; 103(11): 2227–2233. doi:10.1097/TP.0000000000002786Peeters LEJ, Andrews LM, Hesselink DA, de Winter BCM, van Gelder T. Personalized immunosuppression in elderly renal transplant recipients. Pharmacol Res 2018;130:303–307. doi:10.1016/j.phrs.2018.02.031Peeters LEJ, Andrews LM, Hesselink DA, de Winter BCM, van Gelder T. Personalized immunosuppression in elderly renal transplant recipients. Pharmacol Res 2018;130:303–307. doi:10.1016/j.phrs.2018.02.031Хубутия МШ, Шмарина НВ, Дмитриев ИВ. 11-летний опыт повторной трансплантации почки у пожилых реципиентов в НИИ СП им. Н.В. Склифосовского. Вестник трансплантологии и искусственных органов 2019;21(2):31–38Khubutia MS, Shmarina NV, Dmitriev IV. 11-year experience of kidney retransplantation in elderly recipients in Sklifosovsky Research Institute for Emergency Medicine. Russian Journal of Transplantology and Artificial Organs 2019;21(2):31–38 (In Russ.). doi:10.15825/1995-1191-2019-2-31-38Cossart AR, Cottrell NW, Campbell SB, Isbel NM, Staatz CE. Characterizing the pharmacokinetics and pharmacodynamics of immunosuppressant medicines and patient outcomes in elderly renal transplant patients. Transl Androl Urol 2019;8(Suppl 2): S198–S213. doi:10.21037/tau.2018.10.16Cossart AR, Cottrell NW, Campbell SB, Isbel NM, Staatz CE. Characterizing the pharmacokinetics and pharmacodynamics of immunosuppressant medicines and patient outcomes in elderly renal transplant patients. Transl Androl Urol 2019;8(Suppl 2): S198–S213. doi:10.21037/tau.2018.10.16de Boer SE, Sanders JSF, Bemelman FJ, Betjes MGH et al. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients. BMC Nephrol 2021 Jun 2;22(1):208. doi:10.1186/s12882-021-02409-8de Boer SE, Sanders JSF, Bemelman FJ, Betjes MGH et al. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients. BMC Nephrol 2021 Jun 2;22(1):208. doi:10.1186/s12882-021-02409-8Le Meur Y. What immunosuppression should be used for oldto-old recipients? Transplant Rev (Orlando) 2015;29(4): 231–236. doi:10.1016/j.trre.2015.08.004Le Meur Y. What immunosuppression should be used for oldto-old recipients? Transplant Rev (Orlando) 2015;29(4): 231–236. doi:10.1016/j.trre.2015.08.004Zulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011;26(7):783–790. doi:10.1007/s11606-010-1629-xZulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011;26(7):783–790. doi:10.1007/s11606-010-1629-xCorsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 2010;17(6):571–584. doi:10.2174/092986710790416326. Wooten JM. Pharmacotherapy considerations in elderly adults. South Med J 2012;105 (8):437–445. doi:10.1097/SMJ.0b013e31825fed90Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 2010;17(6):571–584. doi:10.2174/092986710790416326. Wooten JM. Pharmacotherapy considerations in elderly adults. South Med J 2012;105 (8):437–445. doi:10.1097/SMJ.0b013e31825fed90Sommerer C, Brunet M, Budde K, Millán O et al. Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study. Br J Clin Pharmacol 2021 Oct;87(10):3851–3862. doi:10.1111/bcp.14794Sommerer C, Brunet M, Budde K, Millán O et al. Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study. Br J Clin Pharmacol 2021 Oct;87(10):3851–3862. doi:10.1111/bcp.14794Gill J, Sampaio M, Gill JS, Dong J, Kuo HT, Danovitch GM et al. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol 2011; 6(5):1168–1178. doi:10.2215/CJN.07540810Gill J, Sampaio M, Gill JS, Dong J, Kuo HT, Danovitch GM et al. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol 2011; 6(5):1168–1178. doi:10.2215/CJN.07540810Karpe KM, Talaulikar GS, Walters GD. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. Cochrane Database Syst Rev 2017;7(7):CD006750. doi:10.1002/14651858.CD006750.pub2Karpe KM, Talaulikar GS, Walters GD. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. Cochrane Database Syst Rev 2017;7(7):CD006750. doi:10.1002/14651858.CD006750.pub2Krenzien F, Quante M, Heinbokel T, Seyda M, Minami K, Uehara H et al. Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. Am J Transplant 2017;17(5):1242–1254. doi:10.1111/ajt.14087Krenzien F, Quante M, Heinbokel T, Seyda M, Minami K, Uehara H et al. Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. Am J Transplant 2017;17(5):1242–1254. doi:10.1111/ajt.14087McDermott JK, Girgis RE. Individualizing immunosuppression in lung transplantation. Glob Cardiol Sci Pract 2018;(1):5. doi:10.21542/gcsp.2018.5McDermott JK, Girgis RE. Individualizing immunosuppression in lung transplantation. Glob Cardiol Sci Pract 2018;(1):5. doi:10.21542/gcsp.2018.5Uptodate.com [Internet]. Kidney transplantation in adults: Kidney transplantation and the older adult patient. [updated 2020 Jan; cited 2020 Dec 11]. Available from: https://www.uptodate.com/contents/kidney-transplantation-in-adults-kidney-transplantationand-the-older-adult-patientUptodate.com [Internet]. Kidney transplantation in adults: Kidney transplantation and the older adult patient. [updated 2020 Jan; cited 2020 Dec 11]. Available from: https://www.uptodate.com/contents/kidney-transplantation-in-adults-kidney-transplantationand-the-older-adult-patientСуслов ДН. Основные принципы иммуносупрессивной терапии после трансплантации почки. Трансплантология 2018; 10(1):42–49Suslov DN. The basic principles of immunosuppressive therapy after kidney transplantation. Transplantologiya. The Russian Journal of Transplantation. 2018;10(1):42–49 (In Russ.). doi:10.23873/2074-0506-2018-10-1-42-49Falck P, Asberg A, Byberg K, Bremer S, Bergan S, Reubsaet JLE et al. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. Transplantation 2008; 86 (10):1379–1383. doi:10.1097/TP.0b013e31818aa4b6Falck P, Asberg A, Byberg K, Bremer S, Bergan S, Reubsaet JLE et al. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. Transplantation 2008; 86 (10):1379–1383. doi:10.1097/TP.0b013e31818aa4b6Robertsen I, Asberg A, Ingero AO, Vethe NT, Bremer S, Bergan S et al. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. Transplantation 2015;99(3):528–532. doi:10.1097/TP.0000000000000384Robertsen I, Asberg A, Ingero AO, Vethe NT, Bremer S, Bergan S et al. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. Transplantation 2015;99(3):528–532. doi:10.1097/TP.0000000000000384Tang JT, de Winter BC, Hesselink DA, Sombogaard F, Wang LL, van Gelder T. The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. Br J Clin Pharmacol 2017;83(4):812–822. doi:10.1111/bcp.13154Tang JT, de Winter BC, Hesselink DA, Sombogaard F, Wang LL, van Gelder T. The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. Br J Clin Pharmacol 2017;83(4):812–822. doi:10.1111/bcp.13154Md Dom ZI, Coller JK, Carroll RP et al. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. Br J Clin Pharmacol 2018 Oct;84(10):2433–2442. doi:10.1111/bcp.13704Md Dom ZI, Coller JK, Carroll RP et al. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. Br J Clin Pharmacol 2018 Oct;84(10):2433–2442. doi:10.1111/bcp.13704Rhu J, Lee KW, Park H, Park JB, Kim SJ, Choi GS. Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience. Ann Transplant 2017 Nov 28;22:707–718. doi:10.12659/aot.906041Rhu J, Lee KW, Park H, Park JB, Kim SJ, Choi GS. Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience. Ann Transplant 2017 Nov 28;22:707–718. doi:10.12659/aot.906041Bozina N, Lalic Z, Nad-Skegro S, Boric-Bilusic A, Bozina T, Kastelan Z et al. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions. Eur J Clin Pharmacol 2017; 73(9):1129–1140. doi:10.1007/s00228-017-2285-4Bozina N, Lalic Z, Nad-Skegro S, Boric-Bilusic A, Bozina T, Kastelan Z et al. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions. Eur J Clin Pharmacol 2017; 73(9):1129–1140. doi:10.1007/s00228-017-2285-4Van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006;17(3):871–880. doi:10.1681/ASN.2005101070Van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006;17(3):871–880. doi:10.1681/ASN.2005101070Kulabusaya B, Vadcharavivad S, Avihingsanon Y, van Gelder T, Praditpornsilpa K. Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. Int J Clin Pharm 2019 Aug;41(4):1047–1055. doi:10.1007/s11096-019-00848-wKulabusaya B, Vadcharavivad S, Avihingsanon Y, van Gelder T, Praditpornsilpa K. Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. Int J Clin Pharm 2019 Aug;41(4):1047–1055. doi:10.1007/s11096-019-00848-wHaller MC, Kammer M, Kainz A, Baer HJ, Heinze G, Oberbauer R. Steroid withdrawal after renal transplantation: a retrospective cohort study. BMC Med 2017;15(1):8. doi:10.1186/s12916-016-0772-6Haller MC, Kammer M, Kainz A, Baer HJ, Heinze G, Oberbauer R. Steroid withdrawal after renal transplantation: a retrospective cohort study. BMC Med 2017;15(1):8. doi:10.1186/s12916-016-0772-6Uptodate.com [Internet]. Glucocorticoid effects on the immune system. [updated 2020 Aug; cited 2020 Dec 27]. Available from: https://www.uptodate.com/contents/glucocorticoid-effectson-the-immune-systemUptodate.com [Internet]. Glucocorticoid effects on the immune system. [updated 2020 Aug; cited 2020 Dec 27]. Available from: https://www.uptodate.com/contents/glucocorticoid-effectson-the-immune-systemSobiak J, Głyda M, Malec M, Chrzanowska M. Pharmacokinetics of Mycophenolate Mofetil Metabolites in Older Patients on the Seventh Day After Renal Transplantation. Transplant Proc 2021; 53(7):2212–2215. doi:10.1016/j.transproceed.2021.07.003Sobiak J, Głyda M, Malec M, Chrzanowska M. Pharmacokinetics of Mycophenolate Mofetil Metabolites in Older Patients on the Seventh Day After Renal Transplantation. Transplant Proc 2021; 53(7):2212–2215. doi:10.1016/j.transproceed.2021.07.003Heinbokel T, Elkhal A, Liu G, Edtinger K, Tullius SG. Immunosenescence and organ transplantation. Transplant Rev (Orlando) 2013;27(3):65–75. doi:10.1016/j.trre.2013.03.001Heinbokel T, Elkhal A, Liu G, Edtinger K, Tullius SG. Immunosenescence and organ transplantation. Transplant Rev (Orlando) 2013;27(3):65–75. doi:10.1016/j.trre.2013.03.001Gabardi S, Tullius SG, Krenzien F. Understanding alterations in drug handling with aging: a focus on the pharmacokinetics of maintenance immunosuppressants in the elderly. Curr Opin Organ Transplant 2015;20(4):424–430. doi:10.1097/MOT.0000000000000220Gabardi S, Tullius SG, Krenzien F. Understanding alterations in drug handling with aging: a focus on the pharmacokinetics of maintenance immunosuppressants in the elderly. Curr Opin Organ Transplant 2015;20(4):424–430. doi:10.1097/MOT.0000000000000220Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab 2011;12(7):601–610. doi:10.2174/138920011796504527Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab 2011;12(7):601–610. doi:10.2174/138920011796504527Jain R, Chung SM, Jain L, Khurana M, Lau SWJ, Lee JE et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 2011;90(1):77–89. doi:10.1038/clpt.2011.104Jain R, Chung SM, Jain L, Khurana M, Lau SWJ, Lee JE et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 2011;90(1):77–89. doi:10.1038/clpt.2011.104Hortal L, Fernandez A, Losada A, Lorenzo M, Baamonde E, Plaza C et al. Study of the cyclosporine concentration at 2 hours in stable renal transplant patients and relation to body mass index. Transplant Proc 2016; 33 (7–8): 3110–3111. doi:10.1016/s0041-1345(01)02326-0Hortal L, Fernandez A, Losada A, Lorenzo M, Baamonde E, Plaza C et al. Study of the cyclosporine concentration at 2 hours in stable renal transplant patients and relation to body mass index. Transplant Proc 2016; 33 (7–8): 3110–3111. doi:10.1016/s0041-1345(01)02326-0David-Neto E, Romano P, Triboni AHK, Ramos F, Agena F, Ebner PAR et al. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. Transplantation 2017; 101(6):1365–1372. doi:10.1097/TP.0000000000001369David-Neto E, Romano P, Triboni AHK, Ramos F, Agena F, Ebner PAR et al. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. Transplantation 2017; 101(6):1365–1372. doi:10.1097/TP.0000000000001369Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ et al. Lower Calcineurin Inhibitor Doses in Older Compared to Younger Kidney Transplant Recipients Yield Similar Troughs. Am J Transplant 2012;12(12):3326–3336. doi:10.1111/j.1600-6143.2012.04232.xJacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ et al. Lower Calcineurin Inhibitor Doses in Older Compared to Younger Kidney Transplant Recipients Yield Similar Troughs. Am J Transplant 2012;12(12):3326–3336. doi:10.1111/j.1600-6143.2012.04232.xMiura M, Satoh S, Kagaya H, Saito M, Inoue T, Tsuchiya N et al. No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. Eur J Clin Pharmacol 2009;65(10):1047–1053. doi:10.1007/s00228-009-0721-9Miura M, Satoh S, Kagaya H, Saito M, Inoue T, Tsuchiya N et al. No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. Eur J Clin Pharmacol 2009;65(10):1047–1053. doi:10.1007/s00228-009-0721-9Wang CX, Meng FH, Chen LZ, Ren B, Li SX, Fei JG et al. Population pharmacokinetics of mycophenolic acid in senile Chinese kidney transplant recipients. Transplant Proc 2007;39(5): 1392–1395. doi:10.1016/j.transproceed.2007.02.082Wang CX, Meng FH, Chen LZ, Ren B, Li SX, Fei JG et al. Population pharmacokinetics of mycophenolic acid in senile Chinese kidney transplant recipients. Transplant Proc 2007;39(5): 1392–1395. doi:10.1016/j.transproceed.2007.02.082Галеев ШР, Галеев РХ, Хасанова МИ, Готье СВ. Сравнительный анализ протоколов индукции иммуносупрессивной терапии у реципиентов почечных трансплантатов (ретроспективный обзор). Вестник трансплантологии и искусственных органов. 2020; 22 (2): 44–52Galeev SR, Galeev RK, Khasanova MI, Gautier SV. Comparative analysis of induction immunosuppressive therapy protocols in renal transplant recipients (retrospective review). Russian Journal of Transplantology and Artificial Organs 2020;22(2):44–52 (In Russ.). doi:10.15825/1995-1191-2020-2-44-52Badowski M, Gurk-Turner C, Cangro C, Weir M, Philosophe B, Klassen D et al. The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Clin Transplant 2009; 23(6):930–937. doi:10.1111/j.1399-0012.2009.01028.xBadowski M, Gurk-Turner C, Cangro C, Weir M, Philosophe B, Klassen D et al. The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Clin Transplant 2009; 23(6):930–937. doi:10.1111/j.1399-0012.2009.01028.xIwamoto H, Nakamura Y, Konno O, Tomita K, Ueno T, Yokoyama T et al. Immunosuppressive Therapy for Elderly Kidney Transplant Recipients. Transplant Proc 2016; 48(3):799–801. doi:10.1016/j.transproceed.2016.02.039Iwamoto H, Nakamura Y, Konno O, Tomita K, Ueno T, Yokoyama T et al. Immunosuppressive Therapy for Elderly Kidney Transplant Recipients. Transplant Proc 2016; 48(3):799–801. doi:10.1016/j.transproceed.2016.02.039Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant 2012;27(2):825–832. doi:10.1093/ndt/gfr374Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant 2012;27(2):825–832. doi:10.1093/ndt/gfr374Haller MC, Royuela A, Nagler EV, Pascual J, Webster AC. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2016;22(8):CD005632Haller MC, Royuela A, Nagler EV, Pascual J, Webster AC. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2016;22(8):CD005632Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010;89(1):1–14. doi:10.1097/TP.0b013e3181c518ccKnight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010;89(1):1–14. doi:10.1097/TP.0b013e3181c518ccKnight SR, Morris PJ. Steroid sparing protocols following nonrenal transplants; the evidence is not there. A systematic review and meta-analysis. Transpl Int 2011;24(12):1198–1207. doi:10.1111/j.1432-2277.2011.01335.xKnight SR, Morris PJ. Steroid sparing protocols following nonrenal transplants; the evidence is not there. A systematic review and meta-analysis. Transpl Int 2011;24(12):1198–1207. doi:10.1111/j.1432-2277.2011.01335.xSteiner RW, Awdishu L. Steroids in kidney transplant patients. Semin Immunopathol 2011;33(2):157–167. doi:10.1007/s00281-011-0259-7Steiner RW, Awdishu L. Steroids in kidney transplant patients. Semin Immunopathol 2011;33(2):157–167. doi:10.1007/s00281-011-0259-7Van Gelder T. Biomarkers in solid organ transplantation. Br J Clin Pharmacol 2017;83(12):2602–2604. doi:10.1111/bcp.13391Van Gelder T. Biomarkers in solid organ transplantation. Br J Clin Pharmacol 2017;83(12):2602–2604. doi:10.1111/bcp.13391Gray JN, Wolf-Doty T, Sulejmani N, Gaber O et al. KidneyCare Guided Immuno-Optimization in Renal Allografts: The KIRA Protocol. Methods Protoc 2020 Sep 30;3(4):68. doi:10.3390/mps3040068Gray JN, Wolf-Doty T, Sulejmani N, Gaber O et al. KidneyCare Guided Immuno-Optimization in Renal Allografts: The KIRA Protocol. Methods Protoc 2020 Sep 30;3(4):68. doi:10.3390/mps3040068Kho M, Cransberg K, Weimar W, van Gelder T. Current immunosuppressive treatment after kidney transplantation. Expert Opin Pharmacother 2011;12(8):1217–1231. doi:10.1517/14656566.2011.552428Kho M, Cransberg K, Weimar W, van Gelder T. Current immunosuppressive treatment after kidney transplantation. Expert Opin Pharmacother 2011;12(8):1217–1231. doi:10.1517/14656566.2011.552428

The authors declare that there are no conflicts of interest present.